Physician profile
Richard E Lloyd
NPI 1073509030
$1,019.58
in general payments reported to CMS, 2019-2025
28 companies · $38.80 in 2025
The $38.80 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $107 · 2021: $154 · 2022: $105 · 2023: $35.66 · 2025: $38.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $107.50 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $91.24 | 2019-2021 | |
| Celgene Corporation | $81.56 | 2022-2023 | Pomalyst |
| Pfizer INC. | $76.84 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $68.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $56.92 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $56.39 | 2019-2020 | |
| Lilly USA, LLC | $44.59 | 2019-2021 | |
| Amgen INC. | $42.42 | 2019-2020 | |
| Genentech USA, INC. | $41.27 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $41.15 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.19 | 2019 | |
| Daiichi Sankyo INC. | $25.89 | 2019 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Foundation Medicine, INC. | $21.58 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19.56 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.38 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.24 | 2020 | |
| Astellas Pharma US INC | $18.92 | 2019 | |
| Agios Pharmaceuticals, INC. | $17.56 | 2019 | |
| Aurobindo Pharma USA, INC. | $16.85 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $16.48 | 2019 | |
| Puma Biotechnology, INC. | $16.19 | 2019 | |
| Emd Serono, INC. | $15.45 | 2019 | |
| Verastem, INC. | $14.85 | 2019 | |
| Array Biopharma INC | $14.06 | 2020 | |
| Rigel Pharmaceuticals, INC. | $13.13 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.